Skippy 1: The Pharmacological Effects of Using Cabozantinib With a Light Breakfast
Study Details
Study Description
Brief Summary
Cabozantinib is a drug which is used to treat metastasized kidney cancer. While it works well, it has a lot of side effects and is quite expensive (€213,- every tablet, €6403,- every month). The standard recommended dose is 60 mg once a day, taken in fasted state. This means patients are not allowed to eat at least 2 hours before and one hour after taking cabozantinib. In daily practice, this is difficult for patients. It might be that by taking with breakfast the chance of side effects like nausea and diarrhea decreases. If patients take cabozantinib with breakfast, the body will have a higher uptake of the drug.
Often the dose of cabozantinib has to be lowered due to side effects. All tablets cabozantinib have the same price, despite how many milligrams are in the tablets. Cabozantinib stays in the body for a long time after ingestion. It takes approximately 120 hours before half of the medicine has left the body. This means it might not be necessary to take cabozantinib every day. Therefore, it is interesting to investigate if taking cabozantinib with breakfast makes it possible to skip taking cabozantinib once in a while. In this study, the investigators want to investigate to what extent the exposure of cabozantinib increases after ingestion with a light breakfast. The results from this study will be used for the development of alternative dosing regimens with cabozantinib tablets of 60 mg taken with a light breakfast including skipping days.
In this study, patients will randomized to start with taking cabozantinib in fasted state (standard regimen) and taking cabozantinib with a light breakfast (experimental regimen). Menu options will be provided. After at least 4 weeks taking cabozantinib according to the randomized regimen, patients will be submitted to the hospital for one day to measure the amount of cabozantinib in the blood at several points of time. This will be measured by venepuncture and fingerprick microsampling. When all blood samples have been collected, the patient will switch to the other regimen. After at least 4 weeks taking cabozantinib according to the second regimen, blood samples will be collected in exactly the same way. After all patients have completed the study, an analysis will be performed to determine the change in exposure to cabozantinib when it is taken with a light breakfast. The results will be used in order to determine the definitive experimental dosing regimens that will be investigated a subsequent study. Patients will be monitored for side effects, especially nausea and/or diarrhea.
The primary goal is to investigate to what extent the exposure of cabozantinib increases by taking cabozantinib with a light breakfast compared to taking cabozantinib in fasted state. The secondary objective is to investigate the analytical feasibility of microsampling (finger prick) for cabozantinib concentration measurements and to monitor side effects.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Standard regimen Patients will continue to use cabozantinib in fasted state, as part of standard of care, in the recommended dose as prior to enrollment in the study. |
|
| Experimental: Experimental regimen Patients will take the prior recommended dose cabozantinib with a light breakfast. |
Other: Light breakfast
Light breakfast, standardized by 7 menu options for patients. All breakfast options contain the same amount of fat (9-10 g). Example of a menu: 150 ml full-fat yoghurt, 40 gram muesli with sugar, 1 glass of tea.
|
Outcome Measures
Primary Outcome Measures
- Area under the concentration-time curve (AUC) [At both hospital admissions after at least 28 days on the regimen (t = 0, 1, 2, 3, 4, 5, 6, 8 and 24 hours)]
Increase of the area under the concentration-time curve (AUC) of the experimental regimen compared to the standard regimen
Secondary Outcome Measures
- Analytical feasibility [At both hospital admissions after at least 28 days on the regimen (t = 0, 1, 2, 3, 4, 5, 6, 8 and 24 hours)]
Analytical correlation/agreement between venapuncture (plasma) measurements and microsampling (whole blood and capillary plasma) measurements
- Adverse events [At inclusion and at both hospital admissions after at least 28 days on the regimen]
The total number of patients experiencing (S)AEs
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Willing and able to provide informed consent;
-
Aged 18 years or older;
-
Histologically confirmed advanced renal cell carcinoma;
-
Receiving cabozantinib as monotherapy as treatment for RCC;
-
At least 4 weeks on a stable dosage of cabozantinib;
-
Acceptable tolerability and the need for dose reductions or treatment interruptions has been estimated as low;
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
-
Estimated life expectancy of ≥ 6 months;
-
No response evaluation planned during the study period;
-
Cabozantinib trough concentration ≤1125 ng/ml in steady state
Exclusion Criteria:
-
Inability to follow the recommended light breakfast;
-
Gastro-intestinal abnormalities influencing the absorption of cabozantinib, including active inflammatory bowel diseases, malabsorption syndrome and prior major surgery of the stomach, pancreas, liver or smaller bowel.
-
Use of moderate or strong inhibitor of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including ketoconazole, grape fruit juice, clarithromycin, erythromycin, itraconazole and ritonavir.
-
Use of moderate or strong inducer of cytochrome P450 enzymes within 1 month of start of treatment with cabozantinib, including rifampicin, phenytoin, carbamazepine, phenobarbital and herbal preparations containing St. John's Wort.
-
Use of inhibitor of multidrug resistance-associated protein 2 within 1 month of start of treatment with cabozantinib, including cyclosporine, delavirdine, efavirenz, emtricitabine, benzbromarone and probenecid.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Leids Universitair Medisch Centrum | Leiden | Zuid-Holland | Netherlands | 2333 ZA |
Sponsors and Collaborators
- dr. Tom van der Hulle
- Leiden University Medical Center
Investigators
- Principal Investigator: Tom van der Hulle, MD PhD, Leiden University Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 81846